U.S. Mortgage Finance Stock News

NasdaqGS:MKTX
NasdaqGS:MKTXCapital Markets

MarketAxess Partnership With Moment Tests New Growth In Advisor Channels

MarketAxess Holdings (NasdaqGS:MKTX) announced a new partnership with Moment. The collaboration connects MarketAxess’s institutional fixed income liquidity and pricing to wealth managers and retail advisors via the Moment platform. The deal extends MarketAxess’s reach beyond traditional institutional clients into larger wealth management and registered investment advisor channels. MarketAxess runs an electronic trading platform focused on corporate and other fixed income securities,...
NYSE:CVSA
NYSE:CVSAConsumer Services

Is Covista (CVSA) Offering Value After Recent Share Price Gains?

This article walks through key numbers to help you judge whether Covista is priced attractively or already fully valued, so you can compare the stock against your own expectations. Covista recently closed at US$118.07, with returns of 4.3% over the last week, 0.1% over the past month, 13.0% year to date and 4.7% over the last year. Recent coverage around Covista has focused on its share price performance and how investors are reassessing the stock in light of broader sector moves. This...
NYSE:CCI
NYSE:CCISpecialized REITs

Is Crown Castle (CCI) Offering Value After Short Term Rebound And Multi Year Slump

If you are wondering whether Crown Castle stock is priced attractively right now, the recent mix of short term gains and longer term weakness makes the valuation story especially interesting. The share price closed at US$89.10, with returns of 3.4% over 7 days and 5.1% over 30 days. Year to date the stock is up 0.5%, but down 12.3% over 1 year, 10.2% over 3 years and 38.1% over 5 years. Recent headlines have focused on Crown Castle's position within U.S. telecom infrastructure and how...
NYSE:RCUS
NYSE:RCUSBiotechs

Is It Too Late To Consider Arcus Biosciences (RCUS) After Its 221% One Year Surge?

If you are wondering whether Arcus Biosciences is reasonably priced or getting ahead of itself, the current share price invites a closer look at what investors may actually be paying for. The stock last closed at US$26.06, with returns of 5.1% over the past 7 days, 13.5% over 30 days, 11.9% year to date, and 220.9% over the last year, which points to a stock that has already seen significant movement. Recent coverage around Arcus Biosciences has focused on its position in the biotech space...
NYSE:NJR
NYSE:NJRGas Utilities

New Jersey Resources (NJR) Margin Compression Tests Clean Energy Growth Narrative In Q2 2026 Results

New Jersey Resources (NJR) has just reported its Q2 2026 results, with Q1 fiscal 2026 revenue at US$604.9 million and EPS of US$1.22 setting the tone for how the year is shaping up for the utility. Over the past few quarters, revenue has ranged from US$298.9 million to US$913.0 million while EPS has moved between a loss of US$0.15 and a high of US$2.04. This gives a clear sense of how earnings and the top line have tracked across different periods. With trailing net margin at 15.2% and the...
NasdaqGS:UPST
NasdaqGS:UPSTConsumer Finance

Is It Time To Reconsider Upstart Holdings (UPST) After Recent Share Price Swings?

If you are wondering whether Upstart Holdings at around US$31.17 is priced for a comeback or still carrying too much risk, the starting point is to understand what the current market value really reflects. The stock has been volatile, with a 5.1% decline over the last 7 days, a 21.9% gain over the last 30 days, a 32.0% decline year to date, and a 39.4% decline over the last year. The 3-year return sits at 121.2%, and the 5-year return at a 65.1% decline. Recent coverage around Upstart often...
NasdaqGM:NTLA
NasdaqGM:NTLABiotechs

ARK Invest’s NTLA Buy Puts Dilution And CRISPR Progress In Focus

ARK Invest recently acquired over 3 million Intellia Therapeutics shares, worth more than US$43 million. The purchase reflects increased institutional interest in Intellia Therapeutics, which trades under ticker NasdaqGM:NTLA. This transaction follows earlier coverage that focused on Intellia's clinical programs, regulatory updates, and financial position. Intellia Therapeutics focuses on CRISPR/Cas9-based therapeutics, an area that many investors watch closely as gene editing moves from...
NasdaqCM:SLNO
NasdaqCM:SLNOBiotechs

A Look At Soleno Therapeutics (SLNO) Valuation After Recent Share Momentum And VYKAT XR Launch Progress

Soleno Therapeutics stock overview Soleno Therapeutics (SLNO) has drawn investor attention after recent share performance, with the stock showing a one-month return of 34.01% and a three-month return of 25.64%. See our latest analysis for Soleno Therapeutics. That recent momentum sits against a mixed longer record, with a 34.01% 1 month share price return and 25.64% 3 month share price return contrasting with a 28.21% 1 year total shareholder return decline but a very large 3 year total...
NasdaqGS:WGS
NasdaqGS:WGSHealthcare

GeneDx Holdings (WGS) Returns To US$17.7 Million Quarterly Loss Challenging Bullish Profitability Narrative

GeneDx Holdings (WGS) opened Q1 2026 with recent quarterly revenue of US$120.99 million in Q4 2025 and a basic EPS loss of US$0.61, alongside trailing 12 month revenue of US$427.54 million and a basic EPS loss of US$0.73. Over the last year, revenue has moved from US$95.64 million in Q4 2024 to US$120.99 million in Q4 2025, while quarterly EPS has swung between a profit of US$0.38 in Q2 2025 and losses of up to US$0.61. This sets up an earnings story that investors may review in terms of how...
NYSE:ITGR
NYSE:ITGRMedical Equipment

Integer Holdings Review Tests Shareholder Value As Profitability Improves

Integer Holdings (NYSE:ITGR) has begun a comprehensive review of its business and capital structure. The Board is assessing options that may include a sale, merger, or other business combination. The review follows heightened external interest in the company and involves financial and legal advisors. The process is focused on assessing ways to maximize value for existing shareholders. Integer Holdings, traded on the NYSE under the ticker ITGR, operates in the medical technology space,...
NYSE:KEYS
NYSE:KEYSElectronic

Is It Too Late To Consider Keysight Technologies (KEYS) After Its Strong Share Price Run?

If you are wondering whether Keysight Technologies at around US$355.93 is a bargain or already pricing in a lot of optimism, the starting point is to understand what the current valuation is actually implying. The stock has shown strong recent momentum, with returns of 7.1% over 7 days, 22.2% over 30 days, 72.3% year to date, 142.9% over 1 year, 148.9% over 3 years and 156.2% over 5 years. This naturally raises questions about how much upside or risk is now baked into the price. Recent...
NasdaqGS:INCY
NasdaqGS:INCYBiotechs

Jakafi XR Approval Tests Incyte Valuation As Growth Outlook Softens

FDA approves Jakafi XR extended-release tablets for myelofibrosis, polycythemia vera and graft-versus-host disease. Jakafi XR offers a once-daily dosing option that differs from existing formulations of ruxolitinib. The approval expands Incyte's Jakafi franchise and broadens its treatment toolkit across several serious blood and immune conditions. For investors watching NasdaqGS:INCY, this latest approval sits at the heart of the company’s core focus in hematology and oncology. Jakafi has...
NYSE:MSA
NYSE:MSACommercial Services

MSA Safety (MSA) Net Margin Decline Tests Bullish Profitability Narratives Heading Into Q1 2026

MSA Safety (MSA) has just opened Q1 2026 earnings season with a run of solid headline figures, capped by Q4 2025 revenue of US$510.9 million and basic EPS of US$2.22. Over recent quarters the company has seen revenue move from US$499.7 million in Q4 2024 to US$421.3 million in Q1 2025 and then back to US$510.9 million in Q4 2025, while quarterly EPS ranged between roughly US$1.51 and US$2.23, setting up a results story where margins and profit quality are front and center for investors. See...